New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin

Ingelheim, Germany, 22 September 2010 – New data from the linagliptin late stage clinical trial programme were presented this week at the 46 ^th Annual Meeting of the European Association for the Study of Diabetes (EASD). The studies included two phase III trials: one investigating linagliptin monotherapy in type 2 diabetes patients for whom metformin therapy is inappropriate, ¹ and the other studying linagliptin as add-on therapy to a sulphonylurea in patients with inadequately controlled type 2 diabetes. ² In addition, a pharmacokinetic study was presented at the congress which investigated linagliptin in a special patient population with different degrees of renal impairment. ³